Artiva Biotherapeutics’ Post

We were thrilled to be with #LupusTherapeutics and @LupusResearchAlliance at the fourth annual Lupus Clinical Investigators Network (LuCIN) Community Meeting, bringing together clinical investigators, study coordinators, people with lupus and industry partners to participate in discussions around critical research initiatives and the latest approaches in lupus treatment. Visit https://bit.ly/LuCIN2024 to learn more about LuCIN. #LupusClinicalResearch #LuCINCommunity #LupusAwarenessMonth

Join us in raising awareness for Lupus Day! #WorldLupusDay #MakeLupusVisible #may10worldlupusday 💜🦋

We say “manufacturing first,” but what does that mean, and why is it important for NK cell therapy? Our Chief Technical Operations Officer, Chris Horan, answers these questions and more for Cell and Gene. Read the article here: https://lnkd.in/dd4Y9pwT #AlloNK #NKcell #NKcells #clinicaltrials #clinicaltrial #autoimmunedisease #lupus #autoimmunity

We are excited to announce that we’ve appointed Neha Krishnamohan as Chief Financial Officer (CFO) and EVP, Corporate Development and promoted Jennifer Bush to Chief Operating Officer. Welcome to the team, Neha, and congrats, Jennifer! Read the full release here: https://lnkd.in/gnrwX4K5  #AlloNK #NKcell #NKcells #clinicaltrials #clinicaltrial #autoimmunedisease #lupus #autoimmunity

We are excited to announce that we’ve dosed our first patient in a Phase 1 clinical trial of #AlloNK in lupus nephritis. Our CEO Fred Aslan said in today’s press release, “To our knowledge, this is the first time a patient has received an allogeneic NK cell therapy candidate in a U.S. clinical trial for treatment of an autoimmune disease. We are encouraged by the activity of AlloNK in our NHL trial, demonstrating AlloNK’s ability to drive B-cell depletion and helping validate the therapy’s potential mechanism of action. Furthermore, our ability to combine AlloNK with CD20, CD19, or CD38 directed monoclonal antibodies gives AlloNK the versatility to target distinct B-cell subpopulations across different autoimmune diseases.” Thank you to the Artiva team for all your hard work supporting the initiation of our multicenter clinical trial! Read the full release here: https://lnkd.in/gM_t_TEN #AlloNK #NKcell #NKcells #clinicaltrials #clinicaltrial #autoimmunedisease #lupus #autoimmunity

“We can do more.” These have been the guiding words from the founding days of Artiva. This is why we are excited to work with Lupus Therapeutics and the @Lupus Research Alliance who will provide clinical operations support to advance AlloNK, an off-the-shelf, allogeneic NK cell therapy, for the treatment of lupus nephritis. Lupus nephritis is a severe autoimmune disease with limited treatment options. Our NK cell therapy has a mechanism very similar to the B-cell targeted autologous CAR-T therapies, but that supports improved access for patients, without the need for apheresis and hospitalization. Read the release here: https://lnkd.in/gqiBGUHx #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis

Next week, our CEO Fred Aslan will be speaking on a key panel to discuss the tremendous opportunity for NK cell therapies and what near-term milestones are coming for the field. If you can’t attend Hanson Wade Group Innate Killers Summit in San Diego next week, this interview with BiotechTV provides great info about our preliminary clinical data in cancer and our upcoming clinical trials in autoimmune disease. To learn more about the conference, visit: https://innate-killer.com/ Watch the BiotechTV interview with Brad Loncar here: https://lnkd.in/gmChSaTD #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis #cancer

Happy #InternationalWomensDay! Today, we celebrate the incredible accomplishments of women all over the globe. At Artiva, we are proud to have a team that champions diversity and inclusion. On this special day, we want to give a shoutout to the incredible women who make up 50% of our team - thank you for your incredible contributions and for inspiring us every day!   #IWD2024 #InspireInclusion #Artivabio

Thanks BiotechTV for chatting with our CEO Fred Aslan about using #NKcell therapies for #autoimmunedisease and #cancer. He describes how Artiva is harnessing the ability of #NKcells to act as a modulator of antibody dependent cellular cytotoxicity as a therapeutic property of its cell therapies. Watch the video below or here: https://lnkd.in/gmChSaTD